TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Time for Community Ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Time for Timed Up and Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % change of HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 day outcomes after transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of CMV and EBV Viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of CMV and EBV Viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Magnitude of CMV and EBV Viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Systemic immune activation following challenge meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma metabolome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Patients Improving 20% in PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: change from baseline in seated DBP at trough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Time Over Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of attacks treated with successful outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of attacks with a partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean visceral pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of RBC units transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ovulation inhibition in Cycle 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Absolute increase in serum creatinine (SCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in biochemical markers of myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Device survivorship
Endpoint domain: Mortality/survival
Primary endpoint: quality of life (EORTC QLQ-C30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: physical functions (6-minute walking test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Free From Target Lesion Revascularization (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Fluorescein Corneal Staining total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of fludarabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wilcoxon statistic (Area Under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predict tumor aggressiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detect functional changes in tumor state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlation between proposed and actual device size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refractive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reperfusion ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatty acid levels at the membrane of the red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent excess body mass index loss (%EBMIL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-care practice
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percent of Subjects Who Healed, Improved, Stayed the Same or Worsened
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Duration of SARS-CoV-2 viral persistence in naso/oropharyngeal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of SARS-CoV-2 viral persistence in stool or rectal swab samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of SARS-CoV-2 viral persistence in semen samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of SARS-CoV-2 viral persistence in breast milk samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of cell immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spatial congruence between operated area and modeled area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects That Achieved Cumulative Maximum Tolerated Dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase II Dose of 177Lu-PSMA-617
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Metastasis Detection Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ocular Convergence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients With Nosocomial MRSA Clinical Cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Structural Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting-State Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meningococcal C serum bactericidal assay antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-polysaccharide C antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccine response to pertussis toxoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Insulin stimulated whole body glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: independent bouts of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: invasive recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in spatial extent of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Dermatologic Sum Score (DSS) at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Relief with Virtual Reality Therapy: Wong-Baker Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Relief with Virtual Reality Therapy: Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Relief with Virtual Reality Therapy: Short-Form McGill Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Predictive Value (PPV) of 68Ga PSMA PET/CT for Detecting Prostate Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Return to Room Air (RTRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improved COVID-19 Clinical Status Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to bevacizumab therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Eating behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cortical Inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance in verbal associative learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: aggregate rating of language skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: aggregate rating of socioemotional skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: aggregate rating motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aggregate rating cognitive skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attention Performance Index (Change From Baseline to Posttreatment)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants With 1 Year Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Serum Erythropoietin (EPO) Levels Above Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the Frequency of Cluster Headache Attacks Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Afatinib
Endpoint domain: Physiological/clinical
Primary endpoint: Change in muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Frailty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Balance Score Standing With Feet Close Together
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Balance Score Standing in Semi Tandem Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Balance Score Standing in Full Tandem Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Score, Standing Test From Chair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of outpatient RSV LRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Disability Severity Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Test repeatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat paracentesis response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of PRFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MACE in 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Death in 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Stroke in 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Proximal serrated polyp detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: prevalence rate of Candiduria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: morbidity rate of underlying diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral State Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 2-hour glucose value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemical Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic Downstaging and Margin Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral oxygen metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma cytokine content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mobility of Tooth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time above MIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in baroreceptor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Somatic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective general health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of days worn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentration-time profiles of SarCNU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma oxycodone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second phase insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Response rate to the administration of Therasphere
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Fat Percent Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SAA clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The number of blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bone borrow hemocytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence rate of dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Brain bioelectrical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC(0-6h)) of Mycophenolate Mofetil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC(0-tau)) of Mycophenolate Mofetil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Mycophenolate Mofetil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Functioning Male
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sexual Functioning Female
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Locoregional Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: NP/pro-BNP from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac arythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of participants admitted to a formal addiction treatment program within thirty days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants treated for an opioid overdose during the 18-month follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pericardial adipose tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacologic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of somatic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression (TTP) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin aesthetic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reliability of the questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adaptive behavior scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global Acne Assessment Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) for Oral Bioavailability of Lamotrigine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction probability for anaesthetic endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Markedly Abnormal Values in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Markedly Abnormal Values in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VNS for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of dysphonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Since Diagnosis of NSCLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Categorized According to Presence of Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of life (EORTC-QLQ-C30 questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: amount of remifentanil delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL-C percent change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High-Frequency power (HF) - Heart Rate Variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total number of prescription medications taken throughout the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total number of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: The total number of new medical conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of days of hospice care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients requiring dose titration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of endovascular treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of endovascular treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Drug and alcohol abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost-effectiveness measured by ICER
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Residual astigmatism (RAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of Hair loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Baseline-adjusted Cmax of PTH(1-84)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Coagulation related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pancreatic infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Absolute and relative changes in systolic and diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of intervention participants achieving BP control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Trajectory of BP changes over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinalysis results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Global photodamage improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Brief Pain Inventory (BPI) Change
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Length of epileptic seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Frequency of epileptic paroxysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: OCT measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovulation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Variation of electric shock amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of CGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of CGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of CGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes